CAR T cells have shown limited efficacy in patients with solid cancers, despite dramatic success in some hematologic malignancies. Preclinical studies showed that the addition of IL-15, which helps T ...

Non-Hodgkin lymphomas either begin in B cells or T cells — T-cell lymphomas account for less than 15 percent of all non-Hodgkin lymphomas. It mainly affects the skin — though they’re not ...

IL-15 enhances the growth and survival of GPC3 CAR T cells, improving their ability to target and fight solid tumors Study: Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.

The team, which published its findings in an article titled, “Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers,” in Nature, tested chimeric antigen receptor (CAR ...